Canada markets closed
  • S&P/TSX

    20,188.43
    +90.93 (+0.45%)
     
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • DOW

    35,061.55
    +238.15 (+0.68%)
     
  • CAD/USD

    0.7961
    -0.0001 (-0.02%)
     
  • CRUDE OIL

    72.17
    +0.26 (+0.36%)
     
  • BTC-CAD

    43,119.59
    -136.05 (-0.31%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • GOLD FUTURES

    1,802.10
    -3.30 (-0.18%)
     
  • RUSSELL 2000

    2,209.65
    +10.17 (+0.46%)
     
  • 10-Yr Bond

    1.2860
    +0.0210 (+1.66%)
     
  • NASDAQ

    14,836.99
    +152.39 (+1.04%)
     
  • VOLATILITY

    17.20
    -0.49 (-2.77%)
     
  • FTSE

    7,027.58
    +59.28 (+0.85%)
     
  • NIKKEI 225

    27,548.00
    +159.80 (+0.58%)
     
  • CAD/EUR

    0.6752
    -0.0008 (-0.12%)
     

Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos, will present at the upcoming Raymond James Virtual Human Health Innovation Conference on Monday, June 21, 2021 at 2:00 PM EDT.

A live webcast of the presentation will be accessible through the Investors/Media section of the Company’s website at www.landosbiopharma.com. Following the event, the webcast will be archived on the Landos website.

About Landos Biopharma

Landos Biopharma is a clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases. LANCE has discovered new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos Biopharma has 17 active development programs targeting these novel pathways at the interface of immunity and metabolism. Lead asset omilancor is a novel gut-restricted small molecule drug candidate for the treatment of ulcerative colitis, Crohn’s disease and Eosinophilic Esophagitis that targets the LANCL2 pathway. NX-13 is a novel, gut-restricted small molecule drug candidate for the treatment of inflammatory bowel disease, that targets the NLRX1 pathway. Additional candidates are in development for the treatment of lupus nephritis, rheumatoid arthritis, multiple sclerosis, and diabetes. For more information, please visit www.landosbiopharma.com.

Contacts:
Michael K. Levitan (investors)
Solebury Trout
646-378-2920
mlevitan@soleburytrout.com

Hannah Gendel (media)
Solebury Trout
646-378-2943
hgendel@soleburytrout.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting